查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1728096

mRNA 平台市場 - 全球產業規模、佔有率、趨勢、機會和預測，按適應症、可用性、mRNA 類型、最終用戶、地區和競爭細分，2020-2030 年預測

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Usability, By mRNA Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 mRNA 平台市場價值為 73 億美元，預計到 2030 年將以 3.56% 的複合年成長率成長。 mRNA（信使 RNA）平台是一項先進的生物技術創新，它使合成 RNA 分子能夠向細胞傳遞遺傳指令，從而促進特定蛋白質的產生。這種方法在疫苗開發中已取得顯著成功，並正在擴展到一系列疾病的治療。值得注意的是，2023 年 9 月，BioNTech SE 與 CEPI 合作，加速開發基於 mRNA 的 Mpox 疫苗，凸顯了該平台在應對新出現的傳染病威脅方面的重要性。透過模仿 RNA 在體內的自然作用，合成的 mRNA 序列被設計來促進免疫反應或支持治療性蛋白質的生產。這些技術由於其適應性、發展速度和有效性而擴大採用，特別是在公共衛生緊急情況和個人化醫療應用中。

市場概覽
預測期 2026-2030
2024年市場規模 73億美元
2030年市場規模 89.3億美元
2025-2030 年複合年成長率 3.56%
成長最快的領域 自我擴增的mRNA
最大的市場 北美洲

關鍵市場促進因素

技術進步

主要市場挑戰

疫苗猶豫和錯誤訊息

主要市場趨勢

虛擬審判數量的增加

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球 mRNA 平台市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按適應症（自體免疫疾病、癌症、傳染病、罕見疾病、呼吸系統疾病）
    • 依可用性（預防性疫苗、治療性藥物、治療性疫苗）
    • 依 mRNA 類型（核苷修飾 mRNA、自擴增 mRNA、未修飾 mRNA）
    • 按最終用戶（醫院和診所、製藥公司、研究機構）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太地區 mRNA 平台市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲mRNA平台市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第8章：北美mRNA平台市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美mRNA平台市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲 mRNA 平台市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球 mRNA 平台市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Amgen Inc. AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • Baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 17266

The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected to grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.30 Billion
Market Size 2030USD 8.93 Billion
CAGR 2025-20303.56%
Fastest Growing SegmentSelf-Amplifying mRNA
Largest MarketNorth America

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Market Players

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

  • Autoimmune Diseases
  • Cancer
    • Personalized Treatment
    • Single Cancer Focused
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases

mRNA Platform Market, By Usability:

  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA

mRNA Platform Market, By End-User:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Organization

mRNA Platform Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
    • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
    • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
    • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Usability
    • 6.2.3. By mRNA Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China mRNA Platform Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Usability
        • 6.3.1.2.3. By mRNA Type
        • 6.3.1.2.4. By End User
    • 6.3.2. India mRNA Platform Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Usability
        • 6.3.2.2.3. By mRNA Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Australia mRNA Platform Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Usability
        • 6.3.3.2.3. By mRNA Type
        • 6.3.3.2.4. By End User
    • 6.3.4. Japan mRNA Platform Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Usability
        • 6.3.4.2.3. By mRNA Type
        • 6.3.4.2.4. By End User
    • 6.3.5. South Korea mRNA Platform Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Usability
        • 6.3.5.2.3. By mRNA Type
        • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Usability
    • 7.2.3. By mRNA Type
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France mRNA Platform Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Usability
        • 7.3.1.2.3. By mRNA Type
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany mRNA Platform Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Usability
        • 7.3.2.2.3. By mRNA Type
        • 7.3.2.2.4. By End User
    • 7.3.3. Spain mRNA Platform Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Usability
        • 7.3.3.2.3. By mRNA Type
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy mRNA Platform Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Usability
        • 7.3.4.2.3. By mRNA Type
        • 7.3.4.2.4. By End User
    • 7.3.5. United Kingdom mRNA Platform Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Usability
        • 7.3.5.2.3. By mRNA Type
        • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Usability
    • 8.2.3. By mRNA Type
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States mRNA Platform Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Usability
        • 8.3.1.2.3. By mRNA Type
        • 8.3.1.2.4. By End User
    • 8.3.2. Mexico mRNA Platform Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Usability
        • 8.3.2.2.3. By mRNA Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Canada mRNA Platform Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Usability
        • 8.3.3.2.3. By mRNA Type
        • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Usability
    • 9.2.3. By mRNA Type
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil mRNA Platform Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Usability
        • 9.3.1.2.3. By mRNA Type
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina mRNA Platform Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Usability
        • 9.3.2.2.3. By mRNA Type
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia mRNA Platform Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Usability
        • 9.3.3.2.3. By mRNA Type
        • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Usability
    • 10.2.3. By mRNA Type
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa mRNA Platform Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Usability
        • 10.3.1.2.3. By mRNA Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Usability
        • 10.3.2.2.3. By mRNA Type
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE mRNA Platform Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Usability
        • 10.3.3.2.3. By mRNA Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Amgen Inc. AstraZeneca PLC
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Asuragen, Inc.
  • 16.3. Catalent Pharma Solutions
  • 16.4. Arcturus Therapeutics, Inc.
  • 16.5. BioNTech AG
  • 16.6. CRISPR Therapeutics Inc.
  • 16.7. AKESOgen, Inc.
  • 16.8. Baseclick GmbH
  • 16.9. Accent Therapeutics Inc.
  • 16.10.Accanis Biotech F&E GmbH & Co KG

17. Strategic Recommendations

18. About Us & Disclaimer